See more : Far East Orchard Limited (O10.SI) Income Statement Analysis – Financial Results
Complete financial analysis of Quotient Limited (QTNT) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Quotient Limited, a leading company in the Medical – Devices industry within the Healthcare sector.
- FIBRA Prologis (FIBRAPL14.MX) Income Statement Analysis – Financial Results
- Netgem SA (ALNTG.PA) Income Statement Analysis – Financial Results
- Hangzhou Changchuan Technology Co.,Ltd (300604.SZ) Income Statement Analysis – Financial Results
- Bite Acquisition Corp. (BITE-WT) Income Statement Analysis – Financial Results
- Axfood AB (publ) (AXFOY) Income Statement Analysis – Financial Results
Quotient Limited (QTNT)
About Quotient Limited
Quotient Limited, a commercial-stage diagnostics company, develops, manufactures, commercializes, and sells products for the global transfusion diagnostics market in the United States, France, Japan, and internationally. The company is developing MosaiQ, a proprietary technology platform, which provides tests for immunohematology, serological disease screening, and molecular disease screening. Its conventional reagent products for blood grouping include antisera products that are used to identify blood group antigens; reagent red blood cells, which enable the identification of blood group antibodies; whole blood control products for use as daily quality assurance tests; and ancillary products that are used to support blood grouping. The company also offers MosaiQ SDS Microarray that is designed as a serological disease screening microarray comprised assays to detect cytomegalovirus and Syphilis; MosaiQ MDS Microarray that is designed as a molecular disease screening microarray test for donor red cells or source plasma; MosaiQ IH Microarray as a blood grouping microarray; MosaiQ Autoimmune Microarray; MosaiQ COVID-19; and MosaiQ IH3 Microarray. It sells its products to hospitals, donor collection agencies, independent testing laboratories, original equipment manufacturers, and blood banking operation and other diagnostics companies. Quotient Limited was founded in 2007 and is headquartered in Eysins, Switzerland.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 38.51M | 43.38M | 32.66M | 29.13M | 24.73M | 22.23M | 18.52M | 18.41M | 19.76M | 14.37M | 12.22M | 10.03M |
| Cost of Revenue | 23.57M | 20.07M | 17.80M | 17.23M | 10.47M | 10.84M | 9.66M | 9.76M | 8.41M | 7.17M | 6.75M | 5.63M |
| Gross Profit | 14.95M | 23.31M | 14.86M | 11.90M | 14.26M | 11.38M | 8.86M | 8.65M | 11.35M | 7.20M | 5.47M | 4.41M |
| Gross Profit Ratio | 38.80% | 53.72% | 45.49% | 40.86% | 57.66% | 51.21% | 47.86% | 46.96% | 57.45% | 50.11% | 44.77% | 43.91% |
| Research & Development | 58.69M | 54.17M | 53.74M | 50.68M | 51.20M | 57.06M | 28.78M | 19.22M | 8.07M | 2.62M | 1.75M | 1.70M |
| General & Administrative | 49.06M | 41.80M | 31.95M | 31.55M | 25.70M | 22.72M | 26.10M | 16.39M | 9.47M | 6.82M | 6.01M | 5.35M |
| Selling & Marketing | 11.02M | 9.85M | 9.85M | 8.64M | 7.35M | 5.66M | 3.07M | 2.75M | 2.71M | 2.25M | 1.67M | 1.46M |
| SG&A | 60.08M | 51.65M | 41.80M | 40.18M | 33.05M | 28.38M | 29.17M | 19.14M | 12.18M | 9.08M | 7.69M | 6.80M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 118.77M | 105.81M | 95.55M | 90.86M | 84.25M | 85.44M | 57.95M | 38.36M | 20.24M | 11.69M | 9.43M | 8.51M |
| Cost & Expenses | 142.34M | 125.89M | 113.35M | 108.09M | 94.72M | 96.29M | 67.61M | 48.12M | 28.65M | 18.86M | 16.18M | 14.13M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 57.00K | 87.00K | 0.00 |
| Interest Expense | 31.95M | 25.92M | 23.86M | 20.02M | 15.37M | 9.90M | 4.15M | 2.32M | 1.08M | 291.00K | 427.00K | 312.00K |
| Depreciation & Amortization | 7.42M | 8.62M | 12.28M | 12.77M | 10.41M | 9.46M | 2.95M | 1.68M | 622.00K | 691.00K | 989.00K | 980.00K |
| EBITDA | -84.80M | -72.01M | -65.98M | -72.56M | -57.22M | -65.71M | -26.78M | -55.07M | -8.47M | -3.73M | -3.06M | -3.33M |
| EBITDA Ratio | -220.17% | -165.99% | -202.04% | -249.05% | -231.35% | -295.61% | -144.60% | -299.15% | -42.86% | -25.97% | -25.02% | -33.18% |
| Operating Income | -92.22M | -82.51M | -80.69M | -78.96M | -69.99M | -74.06M | -49.09M | -29.71M | -8.89M | -4.49M | -3.96M | -4.10M |
| Operating Income Ratio | -239.43% | -190.20% | -247.09% | -271.01% | -282.99% | -333.19% | -265.03% | -161.42% | -45.01% | -31.25% | -32.44% | -40.85% |
| Total Other Income/Expenses | -31.95M | -24.04M | -21.42M | -26.39M | -13.00M | -11.01M | 15.21M | -29.35M | -1.27M | -223.00K | -509.00K | -522.00K |
| Income Before Tax | -124.17M | -106.54M | -102.11M | -105.34M | -82.99M | -85.07M | -33.88M | -59.06M | -10.17M | -4.71M | -4.47M | -4.62M |
| Income Before Tax Ratio | -322.40% | -245.61% | -312.69% | -361.58% | -335.55% | -382.73% | -182.91% | -320.83% | -51.46% | -32.80% | -36.61% | -46.05% |
| Income Tax Expense | 961.00K | 1.93M | 661.00K | 44.00K | -649.00K | -1.11M | 19.36M | -27.03M | -197.00K | 68.00K | -82.00K | -210.00K |
| Net Income | -125.13M | -108.47M | -102.77M | -105.39M | -82.34M | -85.07M | -33.88M | -59.06M | -10.17M | -4.71M | -4.47M | -4.62M |
| Net Income Ratio | -324.89% | -250.05% | -314.71% | -361.73% | -332.92% | -382.73% | -182.91% | -320.83% | -51.46% | -32.80% | -36.61% | -46.05% |
| EPS | -49.11 | -47.35 | -57.41 | -76.82 | -80.65 | -120.90 | -69.29 | -159.91 | -22.13 | -13.12 | -12.45 | -12.86 |
| EPS Diluted | -49.11 | -47.35 | -57.41 | -76.82 | -80.65 | -120.90 | -69.29 | -159.91 | -22.13 | -13.12 | -12.45 | -12.86 |
| Weighted Avg Shares Out | 2.55M | 2.29M | 1.79M | 1.37M | 1.02M | 703.64K | 488.95K | 369.34K | 459.41K | 359.41K | 359.41K | 359.41K |
| Weighted Avg Shares Out (Dil) | 2.55M | 2.29M | 1.79M | 1.37M | 1.02M | 703.64K | 488.95K | 369.34K | 459.41K | 359.41K | 359.41K | 359.41K |
Facebook Ramps Up Privacy Quotient In Latest Move: Find How?
Quotient Limited Announces Departure of Chief Commercial Officer, Jeremy Stackawitz
Quotient Limited's (QTNT) CEO Manuel O. Mendez on Q1 2022 Results - Earnings Call Transcript
Quotient Limited Provides First Quarter Fiscal 2022 Results and Business Update
Quotient Limited Announces Equity Awards
Quotient Limited Announces Departure of Chief Financial Officer, Peter Buhler
New Strong Sell Stocks for June 29th
Zulily Launches First Ever Head & Home Space Quotient in Home Trend Report, Revealing Practical Design Inspiration for More Productivity, Mindfulness and Togetherness
Why Quotient Technology Stock Fell 28% in May
Quotient Limited (QTNT) CEO Manuel Mendez on Q4 2021 Results - Earnings Call Transcript
Source: https://incomestatements.info
Category: Stock Reports